Latest Developments in Global Paraganglioma Treatment Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Paraganglioma Treatment Market

  • Pharmaceutical
  • Upcoming Report
  • Nov 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In October 2023, Enterome revealed updated results from the Phase 1/2 SPENCER trial, assessing EO2401 combined with nivolumab for the treatment of adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP), two types of adrenal tumors. The trial aims to evaluate the safety and efficacy of this combination therapy. The updated data highlights the potential of EO2401 as a promising treatment option for these challenging, rare cancers.
  • In February 2021, Glenmark Pharmaceuticals, a global research-driven company, introduced SUTIB, the generic version of sunitinib oral capsules, in India. This medication is designed to treat kidney cancer and neuroendocrine tumors, offering a more affordable treatment option for patients. The launch reflects Glenmark’s commitment to improving access to essential cancer therapies in emerging markets such as India.

Frequently Asked Questions